| Literature DB >> 28024844 |
Carola G Schipke1, Norman Koglin2, Santiago Bullich2, Lisa Katharina Joachim3, Brigitte Haas4, John Seibyl5, Henryk Barthel6, Osama Sabri6, Oliver Peters4.
Abstract
Today, the use of biomarkers such as amyloid-specific positron emission tomography (PET) tracers and information derived from cerebrospinal fluid (CSF) can support the diagnosis of Alzheimer's disease (AD) as an indicator for the presence of amyloid pathology. We here show that the PET signal of the 18F-labelled tracer florbetaben (NeuraCeq™), that binds to amyloid-beta plaques, inversely correlates with CSF levels of Aß42, another biomarker for AD. Results from the two biomarkers were concordant in 35 out of 38 subjects. In 7 AD subjects (20%) at least one biomarker was inconsistent with the clinical diagnosis. This confirms known limitations of the clinical AD diagnosis and highlights the potential of biomarker-assisted diagnosis to improve accuracy.Entities:
Keywords: Alzheimer's disease; Beta-amyloid; Biomarker; Cerebrospinal fluid; Florbetaben; PET-tracer
Mesh：
Substances：
Year: 2016 PMID： 28024844 DOI： 10.1016/j.pscychresns.2016.10.011
Source DB: PubMed Journal: Psychiatry Res Neuroimaging ISSN： 0925-4927 Impact factor: 2.376